Ventyx prices upsized $151.5 million IPO

Ventyx prices upsized $151.5 million IPO

LONDON, UK: RTW Venture Fund Limited’s portfolio company Ventyx Biosciences Inc. announced pricing of an upsized $151.5 million initial public offering (IPO) and admission to trade on Nasdaq Global Market under ticker “VTYX”.

Ventyx is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with inflammatory and autoimmune diseases.

Ventyx’s pipeline programs include: (1) a selective allosteric TYK2 inhibitor for a broad range of immunological disorders, (2) a tissue selective S1P1R modulator for inflammatory bowel disease (IBD), and (3) a preclinical NLRP3 inhibitor program.

Prior to IPO, the Company, together with other funds managed by RTW Investments, LP, participated in Ventyx’s $114 million financing round in March 2021.

Ventyx’s IPO raised $151.5 million by offering c. 9.5 million shares at $16.00 per share. On the first day of trading, Ventyx’s share price increased by 31.4% to close at $21.02 per share.

Stephanie Sirota, Chief Business Officer of the Investment Manager and Director of the Company, said: “We are excited about Ventyx’s successful IPO and look forward to supporting the company in its efforts to develop innovative therapeutics for patients with inflammatory and autoimmune diseases”.

www.ventyxbio.com

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *